AU2002245486B2 - Treatment of tics, tremors and related disorders - Google Patents

Treatment of tics, tremors and related disorders Download PDF

Info

Publication number
AU2002245486B2
AU2002245486B2 AU2002245486A AU2002245486A AU2002245486B2 AU 2002245486 B2 AU2002245486 B2 AU 2002245486B2 AU 2002245486 A AU2002245486 A AU 2002245486A AU 2002245486 A AU2002245486 A AU 2002245486A AU 2002245486 B2 AU2002245486 B2 AU 2002245486B2
Authority
AU
Australia
Prior art keywords
optionally substituted
compound
disorder
hydrogen
pyrrolidone compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002245486A
Other languages
English (en)
Other versions
AU2002245486A1 (en
Inventor
Gregory Krauss
Harvey Singer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB SA
Original Assignee
UCB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB SA filed Critical UCB SA
Publication of AU2002245486A1 publication Critical patent/AU2002245486A1/en
Assigned to UCB, S.A. reassignment UCB, S.A. Request for Assignment Assignors: JOHNS HOPKINS UNIVERSITY
Application granted granted Critical
Publication of AU2002245486B2 publication Critical patent/AU2002245486B2/en
Assigned to UCB PHARMA, S.A. reassignment UCB PHARMA, S.A. Request for Assignment Assignors: UCB, S.A.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
AU2002245486A 2001-02-23 2002-02-22 Treatment of tics, tremors and related disorders Ceased AU2002245486B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27098701P 2001-02-23 2001-02-23
US60/270,987 2001-02-23
PCT/US2002/005189 WO2002067931A1 (en) 2001-02-23 2002-02-22 Treatment of tics, tremors and related disorders

Publications (2)

Publication Number Publication Date
AU2002245486A1 AU2002245486A1 (en) 2003-03-06
AU2002245486B2 true AU2002245486B2 (en) 2006-11-16

Family

ID=23033711

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002245486A Ceased AU2002245486B2 (en) 2001-02-23 2002-02-22 Treatment of tics, tremors and related disorders

Country Status (6)

Country Link
US (1) US20040116505A1 (enExample)
EP (1) EP1379236A4 (enExample)
JP (1) JP2004523557A (enExample)
AU (1) AU2002245486B2 (enExample)
CA (1) CA2438930A1 (enExample)
WO (1) WO2002067931A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2461961A1 (en) * 2001-10-08 2003-04-17 Ucb, S.A. Use of 2-oxo-1-pyrrolidine derivatives for the treatment of dyskinesia and movement disorders
US7427601B2 (en) * 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
US20070259859A1 (en) * 2006-05-04 2007-11-08 De Bruin Natasja M W J Muscarinic agonists to treat impulse control disorders
ES2336275T3 (es) * 2006-05-04 2010-04-09 Solvay Pharmaceuticals B.V. Agonistas muscarinicos para tratar trastornos del control de impulsos.
BRPI0920342A2 (pt) * 2008-10-16 2020-06-23 The Johns Hopkins University Uso de um inibidor da proteína vesicular sináptica 2a (sv2a) ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica para melhora da função cognitiva, uso de levitiracetam ou um sal farmaceuticamente aceitável do mesmo, uso de brivaracetam ou um sal farmaceuticamente aceitável do mesmo, uso do seletracetam ou um sal farmaceuticamente aceitável do mesmo
EP2533645B1 (en) * 2010-02-09 2016-07-27 The Johns Hopkins University Methods and compositions for improving cognitive function
AU2011293363A1 (en) 2010-08-24 2013-02-28 The Children's Hospital Of Philadelphia Association of rare recurrent genetic variations to attention-deficit, hyperactivity disorder (ADHD) and methods of use thereof for the diagnosis and treatment of the same
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN103044307A (zh) * 2013-01-24 2013-04-17 吉林三善恩科技开发有限公司 以2,4-二羟基苯甲酸为前驱体的吡拉西坦药物共晶及其制备方法
CN103073477A (zh) * 2013-01-24 2013-05-01 吉林三善恩科技开发有限公司 以3,4-二羟基苯甲酸为前驱体的吡拉西坦药物共晶及其制备方法
EP2968237A4 (en) 2013-03-15 2016-08-31 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
CN105142623A (zh) 2013-03-15 2015-12-09 艾吉因生物股份有限公司 用于改善认知功能的方法和组合物
US11219617B2 (en) 2014-05-30 2022-01-11 The Children's Hospital Of Philadelphia Methods of diagnosing and treating autism
JP6766036B2 (ja) * 2014-06-02 2020-10-07 ケトゲン インコーポレイテッド 発作および他の中枢神経系障害および状態の処置のための化合物
CN107810002B (zh) 2015-05-22 2021-01-05 艾吉因生物股份有限公司 左乙拉西坦的延时释放药物组合物
AU2016318786B2 (en) 2015-09-08 2022-04-07 The Children's Hospital Of Philadelphia Methods of diagnosing and treating anxiety disorder

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4620973A (en) * 1980-02-13 1986-11-04 Ciba Geigy Corporation Use of nootropics

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4355027A (en) * 1977-11-02 1982-10-19 Massachusetts Institute Of Technology Process and composition for treating disorders by administering piracetam and choline
GB8412357D0 (en) * 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
JPH0829140B2 (ja) * 1987-04-17 1996-03-27 開成工業株式会社 末▲梢▼循環機能障害診断用皮フ温測定装置
US6107492A (en) * 1998-05-08 2000-08-22 Ucb, S.A. Process for the preparation of levetiracetam
TWI238062B (en) * 1999-12-01 2005-08-21 Ucb Sa A pyrrolidineacetamide derivative alone or in combination for treatment of CNS disorders
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4620973A (en) * 1980-02-13 1986-11-04 Ciba Geigy Corporation Use of nootropics

Also Published As

Publication number Publication date
EP1379236A4 (en) 2009-01-21
EP1379236A1 (en) 2004-01-14
WO2002067931A1 (en) 2002-09-06
JP2004523557A (ja) 2004-08-05
US20040116505A1 (en) 2004-06-17
CA2438930A1 (en) 2002-09-06

Similar Documents

Publication Publication Date Title
AU2002245486B2 (en) Treatment of tics, tremors and related disorders
AU2002245486A1 (en) Treatment of tics, tremors and related disorders
MXPA02005275A (es) Derivado de pirrolidinacetamida solo en combinacion para el tratamiento de trastornos del sistema nervioso central.
AU2002340971B2 (en) Use of 2-oxo-1-pyrrolidine derivatives for the treatment of dyskinesia and movement disorders
AU6895800A (en) Composition comprising a tramadol material and an anticonvulsant drug
MA27596A1 (fr) Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation
CN102512406A (zh) 用于治疗认知障碍的α-氨基酰胺衍生物
CA2500662A1 (en) Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders
AU2009201746A1 (en) [(2-(amino-3,4-dioxo-1-cyclobuten-1-yl)amino]alkyl]-acid derivatives for the treatment of pain
CA2458855A1 (en) Composition for treating parkinson's disease containing a cb1 receptor antagonist and a product activating dopaminergic neurotransmission in the brain
AU772156B2 (en) Compositions comprising GABA analogs and caffeine
JP2009517393A (ja) 不安症の治療方法
JP2004523557A5 (enExample)
Honkavaara Effect of transdermal hyoscine on nausea and vomiting during and after middle ear surgery under local anaesthesia
US6150387A (en) Heterocyclic carboxamide compounds effective in the treatment of drug abuse
EP1658062B1 (en) Alpha-aminoamide derivatives useful as anti-inflammatory agents
AU711625B2 (en) Use of pyrrolidine derivatives in the treatment of alcoholism
CA2535814A1 (en) Pharmaceutical composition comprising an alpha2delta ligand and an opioid receptor antagonist for the prevention and treatment of addiction in a mammal
AU2005237538B2 (en) Methods of diminishing co-abuse potential
WO2019083409A1 (ru) Комбинация и набор с анксиолитическим действием
AU2008213908B2 (en) Treatment of ADHD
HK1064609B (en) 2-(amino-3,4-dioxo-1cyclobuten-1-yl)amino alkyl -acid derivatives for the treatment of pain
MXPA97008875A (en) Use of pyrrolidine derivatives in the preparation of medicines intended for the alcohol treatment
Atkinson Jr et al. Psychiatric medications and pain management in emergency medicine
AU2013248251A1 (en) Treatment of adhd

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: UCB, S.A.

Free format text: FORMER APPLICANT(S): JOHNS HOPKINS UNIVERSITY

PC1 Assignment before grant (sect. 113)

Owner name: UCB PHARMA, S.A.

Free format text: FORMER APPLICANT(S): UCB, S.A.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired